SCHEMBL20320110

SCHEMBL20320110

CC1CCC(O)N1c1ccncc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHKA P35790 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
BCHE P06276 1/20 0.34
GAA P10253 2/20 0.34
RECQL P46063 1/20 0.34
NPC1 O15118 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ADRB2 P07550 1/20 0.32
NCF1 P14598 1/20 0.32
PLD1 Q13393 1/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32
CYP19A1 P11511 1/20 0.32
EED O75530 1/20 0.32
JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9507055 0.86 CHKA (0.41) CHKAHRH3BCHEGAARECQL
SCHEMBL25506006 0.79 HRH3 (0.45) CHKAHRH3BCHEGAARECQL
SCHEMBL25506008 0.69 ADRB2 (0.42) CHKAADRB2NCF1PLD1
Hydrochloric Acid SCHEMBL25183378 0.68 ADRB2 (0.41) CHKAADRB2NCF1PLD1
SCHEMBL49369 0.67 LMNA (0.39) CHKABCHEGAAADRB2NCF1
SCHEMBL16691742 0.66 FFAR4 (0.39)
SCHEMBL16992336 0.66 CCNA2 (0.40) HRH3BCHEKDM4E
SCHEMBL18444563 0.66 CCNA2 (0.40) HRH3BCHEKDM4E
SCHEMBL6864210 0.65 FFAR1 (0.41) GAASMN1; SMN2
SCHEMBL6864215 0.65 FFAR1 (0.41) GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3406609-B1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS NXERA PHARMA UK LTD (GB) 2024-06-26 EP disclosed
US-10196380-B2 Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-02-05 US disclosed
US-20180179184-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196380-B2 Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists CHRM1, CHRM2, CHRM4 CHKA 603/4885HRH3 127/4885BCHE 374/4885
US-20180179184-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 CHKA 603/4885HRH3 127/4885BCHE 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.